In Situ Protein Expression of RRM1, ERCC1, and BRCA1 in Metastatic Breast Cancer Patients Treated with Gemcitabine-Based Chemotherapy

By Metro G.   Zheng Z.   Fabi A.   Schell M.   Antoniani B.   Mottolese M.   Monteiro A. N.   Vici P.   Lara Rivera S.   Boulware D.   Cognetti F.   Bepler G.  

Cancer Investigation, Vol. 28, Iss. 2, 2009-09 ,pp. : 172-180

Informa Healthcare

Access to resources Recommend Favorite

Predictive value of ERCC1 and RRM1 gene single-nucleotide polymorphisms for first-line platinum- and gemcitabine-based chemotherapy in non-small cell lung cancer patients

By                        

Oncology Reports, Vol. 30, Iss. 5, 2013-01 ,pp. : 2385-2398

Spandidos Publications

Access to resources Recommend Favorite

CYP450 polymorphisms predict clinic outcomes to vinorelbine-based chemotherapy in patients with non-small-cell lung cancer

By Pan Ji-Hong   Han Jin-Xiang   Wu Jian-Mei   Sheng Li-Jun   Huang Hai-Nan  

Acta Oncologica, Vol. 46, Iss. 3, 2007-01 ,pp. : 361-366

Informa Healthcare

Access to resources Recommend Favorite

Psychological factors can predict the response to primary chemotherapy in patients with locally advanced breast cancer - report of a feasibility study

By Walker L.G.   Heys S.D.   Walker M.B.   Ogston K.   Miller I.D.   Hutcheon A.W.   Sarkar T.K.   Ah-See A.K.   Eremin O.  

European Journal of Cancer, Vol. 35, Iss. 13, 1999-12 ,pp. : 1783-1788

Elsevier

Access to resources Recommend Favorite

Impact of dihydropyrimidine dehydrogenase and γ-glutamyl hydrolase on the outcomes of patients treated with gemcitabine or S-1 as adjuvant chemotherapy for advanced pancreatic cancer

By                

Experimental and Therapeutic Medicine, Vol. 2, Iss. 6, 2011-01 ,pp. : 1097-1103

Spandidos Publications

Access to resources Recommend Favorite